COVID19 Neurological Manifestation

Study Overview
=================
Brief Summary
-----------------
This study is a prospective observational cohort study to document the prevalence and types of neurological manifestations among hospitalized patients with confirmed or suspected novel coronavirus infection (COVID-19).

Detailed Description
-----------------
This study is a prospective observational cohort study to document the prevalence and types of neurological manifestations among hospitalized patients with confirmed or suspected novel coronavirus infection (COVID-19). Severe acute respiratory syndrome 2 (SARS-CoV-2), the virus that causes COVID-19, shares significant structural and biological similarities with SARS-CoV, which is known to be neuroinvasive particularly with brainstem involvement. There are emerging reports of neurological symptoms associated with COVID-19 infections, including seizures, coma, encephalitis, Guillan-Barre syndrome, and cerebrovascular events including ischemic stroke, ICH, and cerebral venous sinus thromboses. However, the exact prevalence of these conditions and their impact on patient disease severity and outcomes is unknown. As the incidence and severity of COVID-19 infection continue to rapidly rise globally, it is imperative to capture prospective data to accurately document prevalence, severity and clinical characterization of neurological components of COVID 19, the influence of treatment regimens of neurological complications, and role of these confounders on patient and organizational outcomes.

Official Title
-----------------
Neurological Complications of COVID-19

Conditions
-----------------
SARS-CoV 2, Neurologic Manifestations

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients greater than or equal to 18 years old Admitted with suspected or confirmed COVID19 infection Patient exhibiting acute neurological symptoms Exclusion Criteria: Patients under the age of 18 years old Pre-existing, baseline severe neurologic dysfunction including baseline coma/vegetative state, baseline quadriparesis, baseline refractory seizure disorder with frequent breakthrough seizures despite anticonvulsant use

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of neurological manifestations | Proportion of patients with neurological symptoms out of all hospitalized COVID19 patients during study period. | During hospital course, up to 1 month | 
| Hospital Mortality |  | At hospital discharge, approximately 1 month | 
| Global functional outcomes using modified Rankin score | Patients will be assessed on a scale score of 0 (no symptoms at all) to 5 (severe disability; bedridden, incontinent and requiring constant nursing care and attention) | At hospital discharge, approximately 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of ICU stay |  | At hospital discharge, approximately 1 month | 
| Length of hospital stay (in days) |  | At hospital discharge, approximately 1 month | 
| 30-day mortality |  | 30 days from the first day of hospitalization | 
| 90-day mortality |  | 90 days from the first day of hospitalization |